Saniona, a Danish clinical-stage biotech company focused on rare diseases, named Rami Levin its new CEO. Levin was most recently president of the North America unit of Sobi, a rare disease biopharma headquartered in Sweden. He succeeds Jørgen Drejer, a Saniona founder, who will continue as chief scientific officer.
Levin, who will be based in Boston, joins as the company is advancing experimental treatments for disorders including Prader-Willi syndrome and hypothalamic obesity toward commercialization. His previous experience includes leadership roles at Merck Serono.